http://neurotalk.psychcentral.com/sh...d.php?p=109225

with Cogane showed it to be neuroprotective against betya-amyloid and glutamate damage which contributes to Alzheimer's disease.

Cogane works by restoring levels of proteins that are altered in the ageing brain, returning them to levels observed in the young and could even help neural connections in the brain to grow back.

In pre-clinical trials, the drug reversed the decrease of neuronal growth factors as well as reversing neuronal degeneration shown in the ageing brain. If replicated in sufferers, these results could prove a massive breakthrough in treating Alzheimer's.

Cogane is one of Phytopharm's synthetic pharmaceutical molecules, but the company is best known for its products based on plant research.

Its most well-known drug in development is an obesity treatment based on Hoodiagordonii, a rare cactus native to the Kalahari Desert.

Unilever, the global foods giant, has bought exclusive worldwide rights to an appetite-suppressing compound extracted from the Hoodia gordonii plant, which has been developed by Phytopharm.

Unilever says the first new hoodia products are expected to reach the market in the next three years and may be marketed under the SlimFast brand or incorporated in other Unilever brands.

Phytopharm will receive initial payments of around 6.5 million from Unilever, out of a potential total of 21 million as well as royalties once the products go on sale.


http://www.pharmafocus.com/cda/focus...441164,00.html